S871
Clinical - Mixed sites & palliation
ESTRO 2026
Results: The median OS was 9.0 months, with 6- and 12-month survival rates of 63.8% and 34.5%, respectively. In the final multivariate model combining diagnosis- and treatment-related factors (Table 1), higher KPS ( ≥ 70), lung primary, lower extracranial metastasis burden, receipt of chemotherapy, and surgical resection independently predicted longer survival, while radiotherapy modality (SRS vs WBRT) showed no significant effect.All four prognostic indices effectively stratified OS. Based on ROC analysis (Table 2), ds-GPA and BSBM demonstrated the highest predictive accuracy, with AUC values of 0.892 and 0.930 for 6- month survival and 0.931 and 0.899 for 12-month survival, respectively.
importance of individualized, multidisciplinary management strategies in optimizing real-world survival outcomes for patients with brain metastases (3). References: 1. Luo J, Zhu H, Tang Y, Wang H, Zhou X, Lu X, et al. Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy. Int J Clin Exp Med. 2014;72. Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Survival in patients with brain metastases: Updated Diagnosis-Specific Graded Prognostic Assessment and definition of the Eligibility Quotient. J Clin Oncol. 2020;383. Sperber J, Yoo S, Owolo E, Dalton T, Zachem TJ, Johnson E, et al. Validation of the Graded Prognostic Assessment and Recursive Partitioning Analysis in a modern cohort of patients with brain metastases. Neurooncol Pract. 2024; published online Nov 15. Keywords: Brain metastases, prognosis, validation Digital Poster 1368 Survival and fractionation in Metastatic Spinal Cord Compression Sofie Lythcke-Elberling, Anna Mann Nielsen, Gitte Fredberg Persson Oncology, Copenhagen University Hospital, Herlev and Gentofte, Denmark Purpose/Objective: Metastatic spinal cord compression (MSCC) is a painful and potentially debilitating complication of spinal metastases. Most patients are treated with palliative radiotherapy, with regional guidelines recommending 8Gy/1Fx, 25Gy/5Fx, or 30Gy/10Fx based on expected survival. An interim analysis from a phase III trial including patients with MSCC from Herlev Hospital and Rigshospital revealed that clinicians may overestimate survival, leading to potential overtreatment (Nielsen et al., 2023). We conducted a retrospective study to evaluate overall survival in MSCC patients treated in 2022 and its correlation with fractionation. Material/Methods: Patients treated for MSCC at Herlev Hospital in 2022 were identified through electronic patient records using treatment codes. Baseline characteristics, treatment dates, fractionation schedules, and survival data were recorded in a REDCap database. Data were censored on December 31, 2024. Survival was analyzed using Kaplan-Meier estimates and compared with the log-rank test. Results: A total of 243 patients were identified. Median age was
Conclusion: This study validates the clinical applicability of established prognostic indices and suggests that the survival predicted at BM diagnosis is largely determined by the effective delivery of systemic and local therapies. These findings highlight the
Made with FlippingBook - Share PDF online